Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.47 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209704 | 0.87 | AURKA (0.53) | AURKA | |
| SCHEMBL208728 | 0.86 | AURKA (0.47) | AURKATRPC5ADORA2B | |
| SCHEMBL4789994 | 0.85 | AURKA (0.43) | AURKATRPC5ADORA2BCYP2D6 | |
| SCHEMBL211374 | 0.83 | AURKA (0.45) | AURKATRPC5ADORA2B | |
| SCHEMBL13985468 | 0.83 | AURKA (0.41) | AURKATRPC5 | |
| SCHEMBL16152483 | 0.81 | AURKA (0.47) | AURKATRPC5ADORA2B | |
| SCHEMBL210746 | 0.80 | AURKA (0.41) | AURKA | |
| SCHEMBL13985720 | 0.80 | AURKA (0.48) | AURKACYP2D6 | |
| SCHEMBL208160 | 0.79 | AURKA (0.60) | AURKA | |
| SCHEMBL14495792 | 0.79 | AURKA (0.48) | AURKACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |